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Abstract 
Background: The sphenopalatine ganglion (SPG) may be involved in persistent idiopathic facial pain and unilateral 
headaches. The role of SPG blockade via intra oral route in the management of trigeminal neuralgia (TN) is worthy of 
study.
Methods: In this retrospective study, patient records included patients with atypical TN (type 2) that persisted in 
spite of conservative treatment for at least 2 years, and an average pain intensity from the craniofacial region visual 
analogue scale (VAS) before examination. In group I the patients received carmapazepin 800 mg a day for at least 
2 years. In group II 3 ml of local anesthetic agent consisting 2 ml bupivacaine and 1 ml prilocain in addition to 1 ml 
fentanyl, 0.5 ml betametasone disodium phosphate and 0.5 ml opaque was injected by the intraoral route. In this 
group, injection procedures were performed under local anesthesia with fluoroscopic guidance. The Kruskal–Wallis 
and Mann–Whitney U tests with Bonferroni correction were used for intergroup analysis. Age and sex differences were 
evaluated with one-way ANOVA and Fisher’s exact tests, respectively.
Results: Significant differences were found between pre-op and 3rd day VAS values and also pre-op and 1st month 
VAS values. No significant differences were found between pre-op and 6th month VAS values.
Conclusion: The SPG blockade improves the quality of life of patients and a minimally-invasive procedure to man-
agement of TN, when compared to other methods.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
The International Headache Society recently defined 
strict clinical criteria for trigeminal neuralgia (TN) diag-
nosis (Headache Classification Committee of the Interna-
tional Headache Society 2013). Diagnosis of TN consists 
at least three attacks of unilateral facial pain occur fulfill-
ing these criteria; (1) occurring in one or more trigeminal 
nerve division, (2) pain with at least three of the following 
four characteristics that are recurring paroxysmal attacks 
lasting from a fraction of a second to 2 min, severe inten-
sity, electric shock-like shooting–stabbing or sharp in 
quality and precipitated by innocuous stimuli to the 
affected side of the face. In this new classification it has 
been proposed to differentiate TN into two types; type 1 
(previously referred to as classic or typical TN), which is 
an idiopathic episodic pain with the previously reported 
clinical characteristics, lasting several seconds, with 
pain-free intervals between attacks and type 2, describing 
idiopathic trigeminal facial pain that is aching, throbbing, 
or burning pain for more than  % 50 of the time and is 
constant in nature with a minor component of sharp, epi-
sodic pain. It has been also theorized that TN type 1 can 
progress toward TN type 2 and that in this second type, 
the likehood of detecting a structural abnormality such as 
a tumor or a vascular malformation is higher (Eller et al. 
2005). Sphenopalatine ganglion (SPG) may be involved 
in persistent idiopathic facial pain (PIFP) and unilateral 
headaches (Eller et al. 2005; Montano et al. 2015). A few 
motor nerves accompany the SPG sensory trunks. An 
irritation of the SPG motor root may; produce face and 
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neck neuralgias by its connection with the facial nerve 
(FN), lesser occipital and cutaneous cervical nerves; 
account for disturbances in the eye and mandible region 
by its connections with the ciliary and otic ganglions and 
a variety of visceral symptoms by its connection with the 
vagus nerve; cause reflex otalgia by its connection with 
the tympanic plexus (Capra and Dessem 1992; Maarbjerg 
et al. 2014).
Recent research has highlighted the important role 
of the SPG in cerebrovascular autonomic physiology, in 
pathophysiology of cluster and migraine headaches, and 
in conditions of stroke and cerebral vasospasm (Piagkou 
et al. 2012; Day 2001; Broggi et al. 2005). The guidelines 
of American Academy of Neurology (AAN) and the 
European Federation of Neurological Societies (EFNS) 
suggest that carbamazepine (CBZ) and oxcarbazepine 
(OXC) are the first-line medical treatments for pain con-
trol in patients with TN (Cruccu et al. 2008; Attal et al. 
2010). Although pharmacotherapy for the management 
of TN is widely accepted procedure, the side effects, need 
for high doses of medication and finally insensitivity to 
these agents leads to failure of this treatment modal-
ity (Besi et  al. 2015). Therefore surgical and minimal 
invasive management strategies have been developed 
that also suggested by AAN–EFNS as an option for the 
patients refractory to drugs or have adverse reactions 
(Di Stefano et al. 2014). On the other hand success rate 
of these procedures varies considerably. SPG block-
ade via nasal route is a well described procedure for the 
management of TN. Bupivacaine, which is a long lasting 
local anesthetic agent, is applied via transnasal approach 
in this technique. However nasal route requires general 
anesthesia, endoscopic guidance and advanced technical 
skills. On the otherhand SPG blockade via intraoral route 
can be administered under local anesthesia even in office 
settings. Opioids are one of the most effective classes of 
medications available to treat both acute and chronic 
pain. Although its usage in these situations is described 
in literature, the effectiveness of local administration of 
opioids on the management of TN type 2 has not been 
studied before. In this study it was aimed to investigate 
the effectiveness of SPG blockade via intraoral route with 
bupivacaine and fentanyl combination for the manage-
ment of TN type 2.
Methods
In this retrospective study patients who had been 
referred to Baskent University Department of Oral and 
Maxillofacial Surgery and Neurosurgery for management 
of facial pain between October 2011 and February 2015 
were included. The patient selection criteria obtained 
as International Headache Society clinical criteria for 
trigeminal neuralgia.
A total number of 239 patient records were evaluated. 
The patients with other types of trigeminal neuralgia, clus-
ter headache, patients with a history of previous surgical 
attempts to trigeminal neuralgia, diagnosed with multiple 
sclerosis or psycological disorders were excluded. In adddi-
tion patients who did not attend follow-up visits were also 
excluded. A-seventy-six patient (55 female, 21 male) who 
were referred for atypical trigeminal neuralgia between 
October 2011 and February 2015 were included. Group 
I consisted 35 female and 15 males (n = 50) and group II 
consisted 20 female and 6 males (n = 26) patients. Patient 
records were included that patients with atypical trigeminal 
neuralgia (TN type 2) persisted in spite of conservative treat-
ment (oral carbamazepine 800 mg a day) for at least 2 years, 
and an average pain intensity from the craniofacial region 
of  >30  mm on a 0–100  mm visual analogue scale (VAS) 
before examination (Cruccu et  al. 2008). The VAS values 
were evaluated using a scale with two anchor points; zero 
being no pain and ten being the worst pain before the pro-
cedures. Patients with a minimum follow up time for 2 years 
were included whereas patients with other types of trigemi-
nal neuralgia, cluster headache, operated for trigeminal 
neuralgia or psycological disorders were excluded (Cruccu 
et  al. 2008). All patients were informed about the treat-
ment modalities and informed consent form was obtained 
from the patients. Patients were evaluated at four different 
times as pre-operative, early immediate (3  day), immedi-
ate (1 month) and late (6 months) intervals. In group I the 
patients received carbamazepine (CBZ) 800 mg a day for at 
least 2 years. In group II 3 cc of local anesthetic agent con-
sisting 2 cc bupivacaine and 1 cc prilocain in addition to 1 cc 
fentanyl, 1 cc betametasone disosium phosphate (celestone) 
and 1 cc opaque (omniscan) was injected from the intraoral 
route. In this group, injection procedures were performed 
under local anesthesia with fluoroscopic guidance. Patients 
were lay on the operating table and 1 cc of local anesthetic 
was applied to the palatal region of the second and third 
molar area. A-27-gauge dental needle was 60° tilted and 
inserted from 1 cm anterior and 1 cm medial position from 
the 3rd molar area. Needle was passed through from greater 
palatine foramen and it was forwarded to superior-posterior 
direction for an average 2 cm distance. Once the tip of the 
needle reached the SPG under direct visualisation of the 
guidance, the mixture was injected (Figs. 1, 2). 
Outcome measures were pain intensity during daily 
activities such as eating and talking and also patient satis-
faction quantified on VAS evaluation.
The Kruskal–Wallis and Mann–Whitney U tests with 
Bonferroni correction were used for intergroup analy-
sis. Age and sex differences were evaluated with one-way 
ANOVA and Fisher’s exact tests, respectively. Variables 
were presented as the mean ±  SE of the mean, and the 
differences were considered significant at p < 0.01. SPSS 
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17.0 was used for analysis (Statistical Package for the 
Social Sciences, version 17.0, SSPS Inc. Chicago, IL, USA).
Results
Statistically significant differences were found between 
the groups regarding the sex of the patients (p  <  0.01). 
Intra-group and inter-group analysis revealed significant 
female predilection for atypical trigeminal neuralgia. 
The age range of the patients was 27–82 (mean age: 
54.7  ±  11.3) years. No significant differences found 
between the groups regarding the age of the patients 
(p = 0.82).
Medical therapy was recommended for 50 patients in 
group I. The overall mean VAS values decreased from 
8.0 to 3.8 ± 1.29 (VAS max 10–VAS min 0). No signifi-
cant differences were found between pre-op and 3rd 
day VAS values and also pre-op and 1st month VAS val-
ues (p > 0.05). On the other hand significant differences 
were found between pre-op and 6th month VAS values 
(p < 0.05).
SPG blockade was administered for 26 patients in 
group II. The overall mean VAS values decreased from 
8.4 to 2.8 ± 1.03 (VAS max 10–VAS min 0). Significant 
differences were found between pre-op and 3rd day 
VAS values and also pre-op and 1st month VAS values 
(p  <  0.05). On the other hand no significant differences 
were found between pre-op and 6th month VAS values 
(p  >  0.05). In Group I, sleepiness was noted in three of 
50 patients (0.6  %). In Group II, temporary nausea was 
noted in one of 26 patients (0.3 %). No other complica-
tions were noted during the study period.
Intergroup analysis showed time dependent significant 
differences between the groups. Although no signifi-
cant differences were found in pre-treatment evaluation 
between the groups, significant differences were found 
between the groups I and II at 3rd day and 1st month 
VAS values (p < 0.01). On the other hand no significant 
differences were found between the groups I and II at 6th 
month VAS values (p > 0.05).
Discussion
Trigeminal neuralgia (TN) is characterized by a unilat-
eral condition with ultra-short stabbing pain located 
along one or more branches of the trigeminal nerve. The 
primary treatment choice for the TN consists of anti-
epileptics. Carbamazepine (CBZ) and oxcarbazepine 
(OXC) are the frequently used agents; on the other hand, 
nervousness, sleepiness, depression, gum diseases, con-
centration difficulties have been noted in patients (Besi 
et  al. 2015). In addition prolonged TN pain has been 
noted to increase anxiety disorders and cognitive impair-
ments (Wu et al. 2015). On the other hand late resistance 
to OXC and CBZ in cases of prolonged usage has been 
also noted (Di Stefano et  al. 2014). Therefore surgical 
approaches should be kept in mind as recommended by 
AAN–EFNS in refractory cases.
SPG has been identified as the first relay station of 
the autonomic fibers after emerging from the pons sug-
gesting that it may be used therapeutically in autonomic 
imbalance situations and it may play a critical role as a 
Fig. 1 Once the tip of the needle reached the SPG under direct 
visualisation of the guidance, the mixture was injected
Fig. 2 A-27-gauge dental needle was 60° tilted and inserted from 
1 cm anterior and 1 cm medial position from the 3rd molar area. Nee-
dle was passed through from palatinum majus and it was forwarded 
to superior-posterior direction for an average 2 cm distance
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vasodilator to protect the brain against ischemia in 
stroke or ischemia of migraine with aura (Burstein and 
Jakubowski 2005). In addition SPG as a major source for 
postganglionic parasympathetic fibers to the vascular 
beds of the cerebral hemispheres is involved in tone regu-
lation of the cerebral vessels (Piagkou et  al. 2012). Cru-
cial nerve fibers of SPG carrying them trigeminal nerve 
(TGN) in various pain syndromes such as atypical facial 
pain, vasomotor rhinitis, eye disorders, play a role in pain 
due to herpes infections.
TGN’s parasympathetic nerves, petrosal and postgan-
glionic fibers lacrimal, palatine and follow nasal struc-
tures (Haviv et  al. 2015; Benoliel et  al. 2015; Love and 
Coakham 2001). Sensitive fibrils of SPG associated with 
the maxillary nerve. Nucleus salivatorius from the para-
sympathetic nerve ganglia from preganglion geniculi 
with facial nerve fibers reach the ganglion pterygopa-
latina with major petrosus (Capra and Dessem 1992; 
Maarbjerg et al. 2014; Rusu et al. 2009).
As the SPG has an important role on different pain 
syndromes, SPG blockade has an important role on the 
management of TN type 2. Many attempts including the 
removal of SPG cells, known as sphenopalatine gangli-
oneurectomy or radiosurgical neuroablation techniques 
have been described in the literature with varying success 
rates (Cepero et al. 1987; Karas et al. 2008). Besides, min-
imal invasive techniques via transnasal or infrazygomatic 
approaches described for modulating the action of SPG 
with different success rates. Transnasal or also known 
as intranasal approach one of the common approaches 
for the blockade of SPG, but topical anesthetic diffu-
sion with cotton swabs to the SPG is unpredictable and 
the blockade is not durable. In addition nose abnormali-
ties and also blunt surgical access make the success of 
the procedure contradictory. As a solution endoscopic 
transnasal approach was described by Isherwood et  al. 
but the procedure requires endoscopic instrumentation 
and devices (Isherwood and Ansell 2016). Infrazygomatic 
approach has been commonly performed blindly on the 
other hand, SPG block via intra oral route roads safer 
compared to other percutaneous intervention for the 
improvement of acute symptoms, it was quick and effi-
cient (Sanders and Zuurmond 1997). Although intra oral 
route is the most direct way to reach to the SPG, it was 
claimed as difficult, uncertain, and occasionally impossi-
ble to reach by some authors (Piagkou et al. 2012). That 
is partially acceptable because earlier approaches tend 
reach to SPG in a blinded fashion and makes the attempt 
unpredictable. On the other hand in our study group all 
the interventions were performed under the fluoroscopic 
guidance, therefore the procedure was noted as safe and 
predictable. In addition the procedures were performed 
under local anesthesia and well tolerated by the patients 
that were also superiority than the conventional transna-
sal approach. Furthermore more accurate positioning of 
the needle prevents the risk of ocular complications such 
as diplopia as well as blindness.
SPG block is a safe and easy method for the control of 
acute or chronic pain than the other percutaneous treat-
ments for TN management even in office settings. It 
takes only a few moments to implement, and the patient 
can be safely taught to effectively perform this pain 
control procedure at office settings with good expecta-
tions and results. Opioids are one of the most effective 
classes of medications available to treat both acute and 
chronic pain. Opioids act to suppress pain through mu-
receptor activation on priary afferent nerve fibers, dor-
sal horn neurons and supraspinal pain center neurons 
(Sindrup and Jensen 2002). It has been used effectively 
in the management of temporomandibular joint (TMJ) 
pain, cluster headaches, tic douloureux, dysmenorrhea, 
trigeminal neuralgia, bronchospasm and chronic hiccup 
(Peterson et  al. 1995; Davis and Dostrovsky 1988a, b). 
Therefore we carried out our study with opiod usage for 
the SPG blockade that increased success in the patient’s 
medical treatment. Although SPG blockade with bupi-
vacaine injection has been performed and evaluated for 
many other pain syndromes, the combination of fentanyl 
and bupivacaine was found to be an effective way on the 
management of TN type II. On the other hand effective-
ness of bupivacaine alone and mixture of fentanyl with 
bupivacaine should been compared in with larger study 
groups. In addition evaluation of the average distance 
from greater palatine foramen to the SPG and average 
angulation of the needle may be beneficial for performing 
the procedures in clinical settings.
As a conclusion, SPG blockade improves the quality of 
life of patients, though the exact treatment compared to 
other methods. The method is minimally invasive, even 
though it may be done in hospital conditions. The com-
plications during the procedure can be tolerated than the 
other methods are still an advantage for SPG. Further 
clinical studies are recommended with larger groups.
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